PV Bulletin

Evaluation of Therapeutic Equivalence August 2026

The FDA has published final guidance on the Evaluation of Therapeutic Equivalence for drugs and generic drugs, effective from September 2, 2026.

Primary source: Download the Final Guidance Document

PV Impact Brief

Urgency: HighConfidence: high

What changed

The FDA finalized its guidance on therapeutic equivalence evaluations, replacing the draft guidance issued in July 2022.

Why it matters

This guidance influences how therapeutic equivalence is determined for generic drugs, impacting market competition and drug availability.

Action needed

Focus on therapeutic equivalence evaluations for generics

Relevant for
Regulatory Intelligence Lead
Processes impacted
Country ComplianceSignal Management
Owner

Regulatory Intelligence Lead

Review cadence

Ongoing regulatory updates and feedback collection via industry comment opportunities.

Evidence and confidence

Confidence: highSource updated: Sep 2, 2026

Full briefing

Practical implication

Focus on therapeutic equivalence evaluations for generics

The FDA has announced the final guidance document titled “Evaluation of Therapeutic Equivalence” which clarifies the agency's stance on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes) for multisource prescription drugs. This guidance formalizes recommendations previously outlined in a draft issued in July 2022. It aims to assist state health agencies, prescribers, and pharmacists in educational efforts surrounding drug product selection while also containing healthcare costs.

What changed: The FDA finalized its guidance on therapeutic equivalence evaluations, replacing the draft guidance issued in July 2022.

Why it matters: This guidance influences how therapeutic equivalence is determined for generic drugs, impacting market competition and drug availability.

Practical implication: Focus on therapeutic equivalence evaluations for generics

View original source

  • Source: FDA - News and Events for Human Drugs
  • Published at source: 2026-09-02T00:00:00.000Z
  • Discovered by monitor: 2026-09-02T22:07:12.885Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Guidance#Source-ingestion#Regulator-monitor#Usa#Fda.gov

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward